CAR-T cells have undoubtedly proven a promising treatment option for particular groups of patients with R/R B-ALL, DLBCL, and MCL, and follicular lymphoma (FL) as four CD19-redirected products have been granted US FDA approval for medical use [44]. This evidence concerns the gene CD19 and follicular lymphoma.